Marcela V Maus
Harvard University
H-index: 73
North America-United States
Top articles of Marcela V Maus
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Understanding Mechanisms of Response to CAR T-cell Therapy through Single-Cell Sequencing: Insights and Challenges | Nicholas J Haradhvala Marcela V Maus | 2024/3/1 | |
Developing a lenalidomide-inducible safety switch for CAR T cell therapy | Cancer Research | Ditsa Sarkar William Lin Joanna Y Kim Nelson H Knudsen Isabel C Lane | 2024/3/22 |
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma | Clinical Cancer Research | Marc Wehrli Samantha Guinn Filippo Birocchi Adam Kuo Yi Sun | 2024/4/2 |
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology | Gabriele J Kembuan Joanna Y Kim Marcela V Maus Max Jan | 2024/2/13 | |
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7 | Leukemia | Michael C Kann Emily M Schneider Antonio J Almazan Isabel C Lane Amanda A Bouffard | 2024/3 |
Improving CAR T cell efficacy in pancreatic cancer using an in vivo CRISPR Cas9 screen | Cancer Research | Tamina Kienka Felix Korell Nelson Knudsen Kathleen Yates Andi Cheng | 2024/3/22 |
Context matters: Tumor microenvironments impact cellular therapy success | Cell Reports Medicine | Eli P Darnell Marcela V Maus | 2024/4/16 |
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy | Nature Medicine | Bruce L Levine Marcelo C Pasquini John E Connolly David L Porter Michael P Gustafson | 2024/1/9 |
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood | Cytometry Part B: Clinical Cytometry | Won‐Ho Lee Charlotte E Graham Hadley R Wiggin Hannah K Nolan Kiana J Graham | 2024/2/28 |
National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells | Transplantation and Cellular Therapy | Magdi Elsallab Florence Bourgeois Marcela V Maus | 2024/3/16 |
Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma | New England Journal of Medicine | Bryan D Choi Elizabeth R Gerstner Matthew J Frigault Mark B Leick Christopher W Mount | 2024/4/11 |
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | 2024/1/9 | ||
A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help | Blood Advances | Kevin J Curran Sarah Nikiforow Carlos Bachier Yen-Michael Hsu David Maloney | 2024/2/27 |
Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS) | Blood | Magdi Elsallab Moataz Ellithi Matthew A Lunning Christopher D’Angelo Jihyun Ma | 2024/3/15 |
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy | Zandra E Walton Matthew J Frigault Marcela V Maus | 2024/4/7 | |
Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence | bioRxiv | Caleb R Perez Andrea Garmilla Avlant Nilsson Hratch M Baghdassarian Khloe S Gordon | 2024/1/1 |
Genetic retargeting of E3 ligases to enhance CAR T cell therapy | Cell Chemical Biology | Isabel C Lane Gabriele Kembuan Jeannie Carreiro Michael C Kann William Lin | 2024/2/15 |
Chimeric antigen receptor t cells targeting the tumor microenvironment | 2020/4/16 | ||
Tandem CAR-T cells against mesothelin and MUC16ectoto overcome tumor-antigen heterogenicity | Cancer Research | Diego Salas-Benito Filippo Birocchi Alexander Armstrong Amanda A Bouffard Tamina Kienka | 2024/3/22 |
463 Tandem CAR T Cells Targeting EGFRvIII and IL-13R⍺ 2 are Effective Against Heterogeneous Glioblastoma | Neurosurgery | Andrea Schmidts Ambike Srivastava Rishab Ramapriyan Daniel P Cahill Bob S Carter | 2023/4/1 |
Co-Authors
